0 likes | 6 Vues
Orphan products, or drugs developed to treat rare diseases, face unique challenges in the drug development process. Given the small patient population and high research costs, pharmaceutical companies must adopt strategic regulatory pathways to bring these drugs to market efficiently.
E N D